Home › Funds › Lion Point Capital, LP › RGNX

Lion Point Capital, LP position in RGNX

REGENXBIO INC · Health Care

Lion Point Capital, LP reported holding 26,600 shares of RGNX (REGENXBIO INC) in its Q2 2026 13F filing — a position valued at US$319K, representing 1.52% of its reported portfolio and ranking #24 among its reported holdings. Lion Point Capital, LP has disclosed RGNX holdings in 10 of the last 10 reported quarters, going back to Q1 2024.

Latest position (Q2 2026)26.60K sh
Reported value held$318.67K
Portfolio Weight1.52%
First reportedQ1 2024
Last changeHold
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Lion Point Capital, LP's RGNX position evolved

Lion Point Capital, LP first disclosed a stake in RGNX in Q1 2024 at 32,500 shares (US$685K). Across 10 filings, Lion Point Capital, LP increased the stake 2 time(s), trimmed it 1 time(s) and left it unchanged 6 time(s). The most recent filing (Q2 2026) shows 26,600 shares valued at US$319K. Notable position changes include a 59% increase in Q3 2024 (shares fell 26% over the following quarter), a 54% trim in Q4 2025 (shares fell 42% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q1 2024 32.50K $684.77K New
Q2 2024 36.25K $424.12K Add
Q3 2024 57.75K $605.80K Add
Q4 2024 57.75K $446.41K Hold
Q1 2025 57.75K $412.91K Hold
Q2 2025 57.75K $474.13K Hold
Q3 2025 57.75K $557.29K Hold
Q4 2025 26.60K $383.04K Reduce
Q1 2026 26.60K $222.91K Hold
Q2 2026 26.60K $318.67K Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About RGNX and 13F data

RGNX (REGENXBIO INC) is a Health Care company. 34 other funds we track also report a position in RGNX — the largest reported positions include Redmile Group, LLC (US$52.3M), 22NW, LP (US$5.9M), Pale Fire Capital SE (US$5.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding RGNX

All RGNX fund holders →

FAQ

How long has Lion Point Capital, LP held RGNX?

Lion Point Capital, LP has disclosed RGNX holdings in 10 of the last 10 reported quarters, going back to Q1 2024.

What is Lion Point Capital, LP's current position in RGNX?

As of Q2 2026, Lion Point Capital, LP holds 26.60K shares of RGNX (REGENXBIO INC), valued at $318.67K, representing 1.52% of its reported portfolio and ranking #24.

Has Lion Point Capital, LP been buying or selling RGNX?

In the latest 13F filing (Q2 2026), Lion Point Capital, LP held unchanged its position in RGNX.

Which other funds hold RGNX?

Other major institutional holders of RGNX include Redmile Group, LLC, 22NW, LP, Pale Fire Capital SE, among 34 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.